StreetInsider.com News Articles

Tonix Pharmaceuticals CMO to retire in August 2026

Tue, 21 Jul 2026 16:08:47 -0400

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that Chief Medical Officer Dr. Gregory M. Sullivan will retire from his role, effective August 20, 2026.

Tonix Pharmaceuticals CMO to retire in August 2026

Tue, 21 Jul 2026 16:08:47 -0400

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that Chief Medical Officer Dr. Gregory M. Sullivan will retire from his role, effective August 20, 2026.

Form 8-K Tonix Pharmaceuticals For: Jul 20

Tue, 21 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260721/26795602.html

Form 8-K Tonix Pharmaceuticals For: Jul 20

Tue, 21 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260721/26795602.html

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Investing.com -- Raymond James issued an earnings preview for seven commercial-stage biopharmaceutical companies ahead of second-quarter 2026 results, outlining key metrics that could drive stock performance.

For Insmed (NASDAQ:INSM), the firm said Symphony data tracked favorably and believes the narrowing gap between sell-side and buy-side expectations creates a setup for sequential launch growth that could beat 2026 consensus.

United Therapeutics (NASDAQ:UTHR) faces a critical test of whether total Tyvaso revenue returns to sequential growth. Raymond James said a second-quarter Tyvaso print of approximately $480 million to $490 million or better would show that the late first-quarter demand recovery is translating into sales

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Raymond James sees potential for beats across biopharma coverage

Tue, 21 Jul 2026 06:12:05 -0400

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Wed, 15 Jul 2026 09:05:39 -0400

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced the publication of a paper, "Monkeypox virus clade IIb isolate exhibits reduced virulence relative to clade IIa isolates in multiple murine models," in the Journal of Virology, the peer-reviewed publication of the American Society for Microbiology (ASM). The research, conducted at Tonix, found new animal models for investigating mpox pathogenesis and demonstrated significant differences in virulence between the clade IIb circulating in the U.S. and the historic 2003 clade IIa. The manuscript can be accessed at:
https://doi.org/10.1128/jvi.00247-26.

“Global mpox outbreaks that have caused

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Wed, 15 Jul 2026 09:05:39 -0400

“Global mpox outbreaks that have caused

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

Wed, 15 Jul 2026 09:05:00 -0400

Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak